Dr. Mark Silverberg, Dr. David T Rubin, Dr. Laura Targownik, and Dr. Charabaty excitingly discuss why IBD specialists are divided on the topic of therapeutic drug monitoring (TDM). “If the drug is going to work but isn’t present in the body, it doesn’t do its job,” Dr. Rubin said. In addition, when a biologic medicine is present in low concentrations, some patients develop neutralizing antidrug antibodies that clear the substance from the body. “The idea is to monitor the amount of drug, so we can anticipate loss of response by keeping the drug in the body,” he said. Find out what other experts said here.
- What Can We Do To Prevent COVID-19?
- Dr. David T. Rubin and His Colleagues Discuss COVID-19 Vaccines for Patients with IBD
- Dr. Rubin Discusses Advances in Anti-Cytokine Therapy: The Current and Potential Role of IL-12/23 and IL-23 Inhibitors in the Treatment of IBD
- VIDEO: Social media has been a ‘life saver’ during COVID-19 pandemic
- Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study